Top Page
Aptamer Group Plc
(LSE:APTA)
Aptamer Group Plc (APTA) vs. iShares MSCI United Kingdom ETF (EWC)
Aptamer Group Plc Business Overview & Revenue Model
Aptamer Group Plc Financial Statement Overview
| Breakdown | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Mar 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 860.00K | 1.75M | 4.04M | 1.28M | 854.57K |
| Gross Profit | 250.00K | 359.00K | 2.69M | 538.40K | 455.97K |
| EBITDA | -2.81M | -7.36M | -2.19M | -2.24M | -733.59K |
| Net Income | -2.96M | -7.84M | -2.09M | -1.85M | -674.73K |
Balance Sheet | |||||
| Total Assets | 2.77M | 2.75M | 11.52M | 2.06M | 1.39M |
| Cash, Cash Equivalents and Short-Term Investments | 870.00K | 234.00K | 6.69M | 369.00K | 293.15K |
| Total Debt | 817.00K | 69.00K | 1.31M | 78.00K | 160.98K |
| Total Liabilities | 1.88M | 2.45M | 3.47M | 1.96M | 1.14M |
| Stockholders Equity | 887.00K | 304.00K | 8.05M | 105.00K | 245.81K |
Cash Flow | |||||
| Free Cash Flow | -2.41M | -6.09M | -2.79M | -1.26M | -243.54K |
| Operating Cash Flow | -2.28M | -4.06M | -2.38M | -1.10M | -82.71K |
| Investing Cash Flow | -122.00K | -2.03M | -418.00K | -339.20K | -160.79K |
| Financing Cash Flow | 3.04M | -365.00K | 9.12M | 1.50M | -190.51K |
Aptamer Group Plc Technical Analysis
Aptamer Group Plc Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | £11.75M | ― | -333.59% | ― | 45.22% | 55.71% | |
52 Neutral | £2.25M | ― | -50.84% | ― | 418.49% | 27.86% | |
52 Neutral | kr5.49B | 9.89 | -63.86% | 2.02% | 27.11% | 26.73% | |
46 Neutral | £9.71M | ― | -99.43% | ― | 17.39% | 96.02% | |
| ― | £6.14M | ― | -272.62% | ― | ― | ― | |
| ― | £7.14M | ― | -302.41% | ― | ― | ― | |
44 Neutral | £11.65M | ― | -129.49% | ― | 14.12% | 78.16% |
Aptamer Group Plc Corporate Events
Aptamer Group plc announced an investor webinar scheduled for August 7, 2025, where CEO Dr. Arron Tolley and CFO Andrew Rapson will discuss the company’s recent progress, as highlighted in their latest Trading Update. The event, hosted by Turner Pope Investments and chaired by Katie Pilbeam, will include a Q&A session, allowing shareholders and interested parties to engage with the company’s leadership.
Aptamer Group PLC reported a significant 41% increase in revenue for the year ending June 2025, reaching £1.20 million, and strengthened its financial position with a successful post-period fundraise. The company has signed multiple licensing agreements, including royalties from Neuro-Bio and the University of Glasgow, and is advancing its licensing pipeline with global partners. These developments highlight Aptamer’s growing market presence and the potential for sustained revenue streams. Technical advancements, such as the conversion of Alzheimer’s binders to ELISA format and breakthroughs in liver fibrosis treatment, further position the company for commercial success.
Aptamer Group plc announced that all resolutions were passed at its recent General Meeting, allowing the issuance of 266,246,757 Conditional Placing Shares. These shares are set to be admitted to trading on AIM, enhancing the company’s financial position and potentially impacting shareholder interests.
Aptamer Group plc has announced an extension of its collaboration with Unilever, involving additional paid work to further develop its proprietary deodorant Optimers. These Optimers target and inhibit the enzyme responsible for body odor, showing exceptional stability and efficacy in recent tests. The partnership with Unilever, which holds a significant share of the global deodorant market, underscores the potential of Aptamer’s technology to deliver superior personal care solutions and opens opportunities for broader applications, enhancing shareholder value as the company moves towards commercialization.
Aptamer Group plc has issued 2,968,695 new ordinary shares to settle Non-Executive Director fees, specifically for Tim Sykes, covering the period from April to June 2025. This transaction increases Sykes’ total beneficial interest in the company to 11,639,758 shares, representing approximately 0.49% of the company’s issued share capital. The new shares are expected to be admitted to trading on AIM by 24 July 2025, impacting the total voting rights and share capital structure of the company.
Aptamer Group Plc has announced a significant change in its shareholder structure, with Northern Standard Limited acquiring a substantial 9.0589% of the company’s voting rights. This development could potentially impact the company’s strategic direction and influence its market positioning, as it reflects a notable shift in stakeholder interests.
Aptamer Group plc has announced the dispatch of a Circular and Notice of General Meeting to its shareholders, following a proposal to raise £2.0 million through a placing. The General Meeting is scheduled for 24 July 2025, and the results will be shared via the Regulatory News Service and on the company’s website. This move is part of Aptamer’s strategic efforts to bolster its financial position and support its ongoing innovations in the life sciences field.
Aptamer Group plc has raised £2.0 million through a placing of ordinary shares to accelerate the commercialization of its Optimer® technology and strengthen its market position. The funds will support manufacturing investments, enhance licensing negotiations, and launch new services, including biomarker discovery and AI-driven aptamer development. This capital raise is expected to boost the company’s credibility, improve supply chain reliability, and open new opportunities in the life sciences sector, positioning Aptamer as a global leader in aptamer technology.
Aptamer Group plc has announced a significant breakthrough in its liver fibrosis treatment program using its Optimer® platform. The company has identified a novel molecular target that enhances the platform’s potential to deliver targeted gene therapy to liver cells responsible for scarring. This advancement positions Aptamer for strategic licensing discussions with pharmaceutical partners, addressing a critical unmet need in the $20 billion fibrosis market. The Optimer® platform, acting like a ‘magic bullet’, targets scarred liver cells to deliver siRNA, potentially reducing or reversing fibrosis. Laboratory tests have shown promising results, and Aptamer is planning in vivo studies to further evaluate the platform’s efficacy and safety, paving the way for human trials and strategic collaborations.
Aptamer Group plc has entered into a development and licensing agreement with a major global life sciences company to create a custom Optimer®-Fc reagent for immunohistochemistry assays and diagnostic kits. This partnership, which includes a royalty structure, is expected to enhance Aptamer’s recurring revenue potential and expand the application of its Optimer platform in high-value life sciences markets, highlighting the commercial potential and technical capabilities of its technology.
Aptamer Group plc has signed a second development agreement with Unilever to create a new panel of Optimer binders targeting body odour pathways. This collaboration, which follows a successful initial programme, positions Aptamer to expand its presence in the personal care sector, leveraging Unilever’s significant market share and the projected growth of the deodorant market.
Aptamer Group plc has announced new data on its Optimer therapeutic delivery vehicle, which shows promise for treating liver fibrosis and other fibrotic conditions. Presented at the ASGCT Annual Meeting, the data highlights the platform’s adaptability and potential for broad therapeutic application, positioning it as a significant player in the multi-billion-dollar market for fibrotic disease treatments. The collaboration with AstraZeneca and interest from multiple pharmaceutical companies suggest strong future commercial opportunities.
Aptamer Group plc has announced two new development contracts with existing customers, valued at up to £231,000, highlighting the growing commercial traction of its Optimer platform. The company has also entered into licensing agreements with a global enzyme provider, which include milestone payments and royalties, further expanding its revenue streams and reinforcing its strategic focus on sustainable growth. These agreements reflect Aptamer’s increasing influence in the life sciences sector and its commitment to long-term value creation.
Aptamer Group plc has successfully adapted its Optimer-based Alzheimer’s disease test into an ELISA format, enhancing its potential for commercialization in hospital laboratories. The company has also secured a royalty agreement with Neuro-Bio Ltd, allowing it to receive royalties on sales of the diagnostic test. This development is part of a strategic effort to capitalize on the $8.3 billion Alzheimer’s diagnostic market, which is expected to grow significantly. The new test format, which uses non-invasive saliva sampling, promises to improve accessibility and speed up diagnosis, potentially transforming the market by addressing a major unmet clinical need.